Nanotechnology Now





Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > Orphan in need of adoption

Abstract:
Nano therapy for ovarian cancer will enable superior tumor accumulation and retention of radioactivity, resulting in better therapuetic efficacy than existing standards of care.

Orphan in need of adoption

Philadelphia, PA | Posted on December 8th, 2006

Twenty thousand new cases of ovarian cancer are diagnosed in the United States each year. More than 75% of these patients are women with late stage ovarian cancer. The prognosis for this group is very poor: only 30% will survive five years or longer.

Even treatment for ovarian cancer can be devastating to a patient's quality of life. Treatment commonly involves invasive surgery followed by extensive chemotherapy, both of which can be physically and emotionally traumatic.

Under funding received from The Nanotechnology Institute and the National Cancer Institute, University of Pennsylvania Scientists have created a nanotechnology-based radiopharmaceutical that could potentially improve the treatment of ovarian cancer.

The proprietary platform technology specifically targets cancer cells via the folate receptor pathway, minimizing damage to surrounding non-cancerous cells. In principle, the drug will enable a higher tumor radiation dose than is possible with other radiotherapeutics, which do not deliver enough radiation to be useful for treatment.

Unfortunately, despite tremendous laboratory progress, this technology may never reach the patients who need it most. The reason is that the market opportunity for ovarian cancer is small (~$75M/year) - too small to justify development by a large multinational corporation.

"This is a platform technology with enormous potential, but its early stage means there is also enormous clinical risk," says Dr. Brian Smith, a co-inventor of the technology. "Our work with Greg Adams at the Fox Chase Cancer Center is promising, but it suggests the need for additional experiments."

Usually at this stage of development, a sponsoring company would invest and work with the scientist to further the research. However, the small market size is a significant barrier to attracting would-be investors. Dr. Smith also hopes to keep the drug affordable, launching at a price of around $5,000 instead of the $50,000 that could be charged for this type of therapy.

"What we need is an angel with personal interest," says Hugo Fitzgerald, Manager of Nanotechnology and Licensing at the University of Pennsylvania. "We have an adequate IP portfolio to justify the creation of a small start up, what we lack is the outside management to champion it and push it out of the laboratory and into the FDA approval process."

The therapeutic would likely qualify for tax credits and marketing exclusivity under the Orphan Drug Act, priority FDA review, and accelerated FDA approval. Follow on applications could include treatments for various other cancers as well as a related radiopharmaceutical for diagnostic imaging.

If interested in working with or supporting the research, please contact:

Hugo FitzGerald
Manager Nanotechnology and Licensing
Center for Technology Transfer
University of Pennsylvania

####

For more information, please click here

Contacts:
Contact: Hugo FitzGerald
Phone: 215 573 4307
Fax:
E-mail:

Copyright © University of Pennsylvania

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Investments/IPO's/Splits

Harris & Harris Group Portfolio Company, AgBiome, Announces Partnership to Accelerate the Discovery of Next Generation Insect-Resistant Crops July 1st, 2015

Nanometrics to Participate in 7th Annual CEO Investor Summit 2015: Investor Event Held Concurrently With SEMICON West in San Francisco June 25th, 2015

Harris & Harris Group Portfolio Company D-Wave Systems Announces 1,000 Qubit Processor and is Discussed in the Economist June 23rd, 2015

Nanowire LED Innovator Aledia Completes $31 Million Series B Financing June 18th, 2015

Nanomedicine

A Stretchy Mesh Heater for Sore Muscles July 6th, 2015

New Biosensor Produced in Iran to Detect Effective Drugs in Cancer Treatment July 4th, 2015

Groundbreaking research to help control liquids at micro and nano scales July 3rd, 2015

Iranian Scientists Find Simple, Economic Method to Synthesize Antibacterial Nanoparticles July 2nd, 2015

Announcements

Surfing a wake of light: Researchers observe and control light wakes for the first time July 6th, 2015

Tel Aviv/Tsinghua University project uses crowd computing to improve water filtration: The research, a product of the new TAU-Tsinghua XIN Center, was conducted by 150,000 volunteers at IBM's World Community Grid July 6th, 2015

Transition from 3 to 2 dimensions increases conduction, MIPT scientists discover July 6th, 2015

A Stretchy Mesh Heater for Sore Muscles July 6th, 2015

Human Interest/Art

Renishaw's inVia confocal Raman microscope system is being used in conservation activities at the Rijksmuseum in Amsterdam, the Netherlands June 16th, 2015

New sensing tech could help detect diseases, fraudulent art, chemical weapons June 1st, 2015

INSIDDE: Uncovering the real history of art using a graphene scanner May 21st, 2015

Winner Announced for NNI’s First ‘EnvisioNano’ Nanotechnology Image Contest May 6th, 2015

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More










ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project